Convergent Modifiers of Exposure Variability in Approved Cannabinoid Medicines: Pharmacogenomics, Drug–Drug Interactions, and Parent–Metabolite Divergence

Amina M. Bagher

Background/Objectives: Systemic exposure to the approved cannabinoid medicines cannabidiol, nabiximols, dronabinol, and nabilone varies markedly among patients. Genotype and comedication may act at shared clearance steps and alter parent-drug and active-metabolite exposures differently. This review integrates pharmacogenomic, drug–drug interaction, and post-approval safety evidence within a convergent exposure-mod…